ARTL

Company Overview — What Does ARTELO BIOSCIENCES, INC. Do?

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California. ARTELO BIOSCIENCES, INC. (ARTL) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Gregory D. Gorgas and employs approximately 5 people. With a market capitalization of $6M, ARTL is one of the notable companies in the Healthcare sector.

ARTELO BIOSCIENCES, INC. (ARTL) Stock Rating — Hold (April 2026)

As of April 2026, ARTELO BIOSCIENCES, INC. receives a Hold rating with a composite score of 34.0/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.ARTL ranks #1,925 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ARTELO BIOSCIENCES, INC. ranks #205 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ARTL Stock Price and 52-Week Range

ARTELO BIOSCIENCES, INC. (ARTL) currently trades at $5.87. The stock lost $0.64 (9.8%) in the most recent trading session. The 52-week high for ARTL is $28.60, which means the stock is currently trading -79.5% from its annual peak. The 52-week low is $0.82, putting the stock 616.2% above its annual trough. Recent trading volume was 212K shares, suggesting relatively thin trading activity.

Is ARTL Overvalued or Undervalued? — Valuation Analysis

ARTELO BIOSCIENCES, INC. (ARTL) carries a value factor score of 13/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth.

At current multiples, ARTELO BIOSCIENCES, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ARTELO BIOSCIENCES, INC. Profitability — ROE, Margins, and Quality Score

ARTELO BIOSCIENCES, INC. (ARTL) earns a quality factor score of 15/100, signaling below-average profitability metrics relative to the broader market. Return on assets (ROA) comes in at -230.7% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ARTL Debt, Balance Sheet, and Financial Health

Balance sheet data for ARTL is evaluated through our stability factor. The current ratio is 0.38x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $875,000. Cash and equivalents stand at $2M.

ARTL has a beta of -2.37, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for ARTELO BIOSCIENCES, INC. is 28/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

ARTELO BIOSCIENCES, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, ARTELO BIOSCIENCES, INC. reported revenue of $0 and earnings per share (EPS) of $-3.97. Net income for the quarter was $-10M. Operating income came in at $-10M.

In Q3 2025, ARTELO BIOSCIENCES, INC. reported revenue of $0. Net income for the quarter was $-3M. Operating income came in at $-3M.

In Q2 2025, ARTELO BIOSCIENCES, INC. reported revenue of $0. Net income for the quarter was $-3M. Operating income came in at $-3M.

In Q1 2025, ARTELO BIOSCIENCES, INC. reported revenue of $0. Net income for the quarter was $-2M. Operating income came in at $-2M.

Over the past 8 quarters, ARTELO BIOSCIENCES, INC. has experienced revenue contraction from $0 to $0. Investors analyzing ARTL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ARTL Dividend Yield and Income Analysis

ARTELO BIOSCIENCES, INC. (ARTL) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ARTL Momentum and Technical Analysis Profile

ARTELO BIOSCIENCES, INC. (ARTL) has a momentum factor score of 74/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 38/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

ARTL vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ARTELO BIOSCIENCES, INC. (ARTL) ranks #205 out of 838 stocks based on the Blank Capital composite score. This places ARTL in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ARTL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ARTL vs S&P 500 (SPY) comparison to assess how ARTELO BIOSCIENCES, INC. stacks up against the broader market across all factor dimensions.

ARTL Next Earnings Date

No upcoming earnings date has been announced for ARTELO BIOSCIENCES, INC. (ARTL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ARTL? — Investment Thesis Summary

ARTELO BIOSCIENCES, INC. presents a balanced picture with arguments on both sides. The quality score of 15/100 flags below-average profitability. The value score of 13/100 indicates premium valuation. Price momentum is positive at 74/100, suggesting the trend favors buyers. High volatility (stability score 28/100) increases portfolio risk.

In summary, ARTELO BIOSCIENCES, INC. (ARTL) earns a Hold rating with a composite score of 34.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ARTL stock.

Related Resources for ARTL Investors

Explore more research and tools: ARTL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ARTL head-to-head with peers: ARTL vs AZN, ARTL vs SLGL, ARTL vs VMD.